FDA has approved Komzifti (ziftomenib) as the first once-daily, oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, supported by Phase II KOMET-001 data showing meaningful ...
Data-driven planning aids in the design of feasible clinical trials from the outset, by simulating enrollment before the ...
In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback